Copyright
©The Author(s) 2017.
World J Diabetes. Mar 15, 2017; 8(3): 112-119
Published online Mar 15, 2017. doi: 10.4239/wjd.v8.i3.112
Published online Mar 15, 2017. doi: 10.4239/wjd.v8.i3.112
Gene | Genotype (n = 252) | Micro-albuminuric group (n = 170) | Macro-albuminuric group (n = 82) | ||||
R (%) (n = 76) | NR (%) (n = 94) | P-value1 | Rc (%) (n = 45) | NR (%) (n = 37) | P-value2 | ||
ACE (I/D) | II | 23 (45) | 28 (55) | 0.974 | 15 (56) | 12 (44) | 0.636 |
ID | 42 (44) | 53 (56) | 20 (53) | 18 (47) | |||
DD | 11 (49) | 13 (54) | 10 (59) | 7 (41) | |||
AGT (M235T) | MM | 25 (60) | 17 (40) | 0.11 | 9 (47) | 10 (53) | 0.201 |
MT | 36 (40) | 53 (60) | 23 (51) | 22 (49) | |||
TT | 15 (38) | 24 (62) | 13 (72) | 5 (28) |
- Citation: Aggarwal N, Kare PK, Varshney P, Kalra OP, Madhu SV, Banerjee BD, Yadav A, Raizada A, Tripathi AK. Role of angiotensin converting enzyme and angiotensinogen gene polymorphisms in angiotensin converting enzyme inhibitor-mediated antiproteinuric action in type 2 diabetic nephropathy patients. World J Diabetes 2017; 8(3): 112-119
- URL: https://www.wjgnet.com/1948-9358/full/v8/i3/112.htm
- DOI: https://dx.doi.org/10.4239/wjd.v8.i3.112